Anti-Rheumatic Drugs - NAFTA | Statista Market Forecast

The Anti-Rheumatic Drugs market is anticipated to witness significant growth in revenue, with a projected value of US$35.39bn by the year 2024.
This market is expected to exhibit a steady annual growth rate (CAGR 2024-2029) of -1.22%.
As a result, the market volume is predicted to reach US$33.27bn by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, with an estimated value of US$34.70bn in 2024.
The NAFTA region, consisting of the United States, Canada, and Mexico, plays a significant role in shaping the Anti-Rheumatic Drugs market landscape.
In the NAFTA region, the demand for anti-rheumatic drugs is on the rise due to an aging population and increasing awareness about the importance of early diagnosis and treatment.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in NAFTA has been experiencing a steady growth in recent years.

Customer preferences: The increasing prevalence of rheumatoid arthritis and other autoimmune diseases has led to a rise in demand for anti-rheumatic drugs in the NAFTA region. Patients are also seeking more effective and convenient treatment options, which has led to a shift towards biologic drugs over traditional disease-modifying antirheumatic drugs (DMARDs).

Trends in the market: The United States dominates the Anti-Rheumatic Drugs market in NAFTA, accounting for the majority of the region's revenue. However, Mexico is expected to experience the highest growth rate in the market due to an aging population and increasing healthcare expenditure. Biologic drugs are also expected to continue their dominance in the market, with newer drugs such as JAK inhibitors and biosimilars gaining traction.

Local special circumstances: In Canada, the government's strict drug pricing regulations have led to slower market growth compared to the US and Mexico. However, the recent implementation of the Biosimilar Initiative is expected to increase the use of biosimilars and reduce healthcare costs. In Mexico, the availability of biosimilars has been limited due to regulatory hurdles, but recent regulatory changes are expected to increase their availability and usage.

Underlying macroeconomic factors: The increasing prevalence of autoimmune diseases, particularly in an aging population, is a key driver of the Anti-Rheumatic Drugs market in NAFTA. The rising healthcare expenditure and increasing demand for effective treatment options are also contributing to the market's growth. The ongoing COVID-19 pandemic has had a mixed impact on the market, with disruptions in supply chains and reduced patient visits to healthcare facilities leading to a temporary slowdown in market growth. However, the pandemic has also highlighted the importance of managing autoimmune diseases, which is expected to contribute to the market's long-term growth.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.